SL Science Holding Ltd (SLBT) Stock Score, Valuation & Financial Research

SL Science Holding Ltd is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for SLBT

SL Science Holding Ltd does not currently have a complete Wall Street Score. The stored market price is USD 1.63. These figures are a research snapshot, not a buy or sell recommendation.

What SL Science Holding Ltd does

SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company’s products include SL bio’s milk-derived exosome essence, SL bio’s tangerine-derived extract, and the MilkExo concentrate series. It also offers research services in armed T-cells, gamma delta T- cells, citrus reticulata (tangerine) extract, and milk-derived exosomes. SL Science Holding Limited was formerly known as SL BIO Co., Ltd. and changed its name to SL Science Holding Limited in June 2026. The company is based in Taipei, Taiwan.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

SL Science Holding Limited is a biomedical company that operates through its subsidiary, SL Bio, to develop innovative cellular and gene therapies. The company is transitioning its business model from direct retail sales of exosome concentrate products to individual end-users and corporate customers toward a wholesale model involving corporate distributors.

Products and services

  • Proprietary cell expansion, bispecific antibody engineering platforms, and legacy exosome commercial operations, with a focus on Gamma Delta T cell therapies for solid tumor indications.

Brands and product families

  • SL Science — Primary corporate brand for cellular and gene therapy operations. Source

Customer types

Corporate distributors; Individual end-users.

Business strengths to evaluate

  • Proprietary cell expansion and bispecific antibody engineering platforms Source

Business risks and research considerations

  • Business transformation and transition of sales model Source

Sources: Company research source · SL Science

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

SLBT financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.63
Market capitalization:
915.44M (currency not supplied)
Revenue:
USD 2.2M
Net income:
USD -3.82M
Free cash flow:
USD -2.23M
Cash:
USD 1.26M
Total debt:
USD 213.41K
EPS:
USD 0.00

What stands out

  • Reported year-over-year revenue growth is -34.7%.
  • Free cash flow is USD -2.23M, negative for the stored period.
  • The balance sheet shows USD 1.26M of cash versus USD 213.41K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -101.5% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -173.8% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 1.05M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for SLBT

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • What is driving SLBT's revenue decline, and does the latest filing suggest the weakness is temporary or structural?
  • How long can SLBT fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is SLBT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for SLBT to reach sustainable profitability?
  • What does the current share basis reconciled warning mean for the reliability or interpretation of SLBT's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research SLBT

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.